الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 148 |  |  |
| | | from | 148 | | |
Abstract
Pegifn-a/RBV remains the standard of care for patients with HCV non genotypel,and is associated with modest SVR rates in genotype4,which accounts for 90% HCV infections in egypt.